Lleida Study Reveals Impact of Chronic Kidney Disease on Cardiovascular Risk
The research, led by IRBLleida and UdL, uses a new minipig model to analyze atherosclerosis.
By Pere Roca Soler
••2 min read
IA
Generic image of scientific research in a laboratory
Pioneering research, spearheaded from Lleida, has demonstrated that chronic kidney disease (CKD) profoundly alters lipid metabolism and accelerates the development of atherosclerosis, a key factor in cardiovascular diseases.
The study, published in the journal Laboratory Animal Research, utilized an innovative experimental model involving minipigs. The translational vascular and renal research group at the Lleida Institute for Biomedical Research (IRBLleida) induced CKD in these animals through a minimally invasive intervention and monitored them for over a year using imaging techniques and molecular analyses.
“
"Although rodent models have been useful for studying these processes, they have limitations in analyzing the evolution of the disease with imaging techniques similar to those used in humans. To overcome this limitation, this study develops a new experimental model with minipigs, which have a physiology more similar to humans."
The results obtained reveal that animals with CKD develop impaired renal function and a much faster progression of atherosclerosis. This condition leads to increased calcification and larger fat plaques in the arteries. Furthermore, CKD causes significant changes in inflammation and lipid metabolism.
“
"This work reinforces the idea that chronic kidney disease is a primary cardiovascular risk factor and highlights the importance of identifying early biomarkers that allow for the detection and monitoring of disease progression. Additionally, the results open the door to the development of new therapeutic strategies."
The research, led by IRBLleida and the University of Lleida (UdL), involved collaboration from various national and international institutions, including the National Center for Cardiovascular Research Carlos III, Aarhus University in Denmark, the Canary Islands University Hospital Complex, the University of La Laguna in Tenerife, the University of Extremadura, and the Pere Virgili Health Research Institute (IISPV).
The project received funding from the Lleida Institute for Biomedical Research, the Ministry of Science, Innovation and Universities, the Carlos III Health Institute, the European Regional Development Fund 'a way to build Europe', and the Lleida Provincial Council.